Our findings suggest that GM1 treatment in both KO and HT mice, despite the severity of the disease in the KO mice, can alleviate motor and short‐term spatial memory dysfunctions and may lead to the development of a clinically relevant treatment for GM3 synthase deficiency. This evidence concerns the gene ST3GAL5 and hematocrit.